Molecular markers to guide primary radical treatment selection in localized prostate cancer

Expert Review of Molecular Diagnostics

Volumn 14, Issue 7, 2014, Pages 871-881

  Gnanapragasam, Vincent J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

biomarker; predictive; prostate cancer; radical prostatectomy; radiotherapy; tailored therapy; treatment specific

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CD147 ANTIGEN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; MICRORNA; MOLECULAR MARKER; MYC PROTEIN; PERIPHERAL MYELIN PROTEIN 22; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P16; PROTEIN P53; UROKINASE; UVOMORULIN; VASCULOTROPIN; TUMOR MARKER;

ANDROGEN DEPRIVATION THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; DISEASE SURVEILLANCE; EPITHELIAL MESENCHYMAL TRANSITION; EXTERNAL BEAM RADIOTHERAPY; HUMAN; IONIZING RADIATION; MOLECULAR PATHOLOGY; PRIMARY TUMOR; PROSTATE CANCER; PROSTATECTOMY; REVIEW; ROBOTICS; SALVAGE THERAPY; SYSTEMIC THERAPY; TREATMENT FAILURE; CHROMOSOME ABERRATION; GENETICS; MALE; PERSONALIZED MEDICINE; PROCEDURES; PROSTATIC NEOPLASMS;

CHROMOSOME ABERRATIONS; HUMANS; INDIVIDUALIZED MEDICINE; MALE; PROSTATIC NEOPLASMS; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 84906315745     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2014.936851     Document Type: Review

References (102)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61(2):69-90
2. Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59(1):61-71
3. National Institute for Health and Clinical Excellence. Referral guidelines for suspected cancer. Clinical guideline 27. National Institute for Health and Clinical Excellence; London: 2005
4. Cidon EU, Ellis SG, Inam Y, et al. Molecular targeted agents for gastric cancer: A step forward towards personalized therapy. Cancers (Basel) 2013;5(1):64-91
5. Sonpavde G, Choueiri TK. Precision medicine for metastatic renal cell carcinoma. Urol Oncol 2014;32(1):5-15
6. Hudson TJ. Genome variation and personalized cancer medicine. J Intern Med 2013;274(5):440-50
7. Garzotto M, Myrthue A, Higano CS, Beer TM. Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. Urol Oncol 2006;24(3):254-9
8. Vuky J, Porter C, Isacson C, et al. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer. Cancer 2009;115(4):784-91
9. Gnanapragasam VJ, Mason M, Shaw G, Neal DE. The role of surgery in high risk localised prostate cancer. BJU Int 2012; 109(5):648-58
10. Roychowdhury S, Chinnaiyan AM. Advancing precision medicine for prostate cancer through genomics. J Clin Oncol 2013;31(15):1866-73
11. Spans L, Clinckemalie L, Helsen C, et al. The genomic landscape of prostate cancer. Int J Mol Sci 2013(6):10822-51
12. Schmidt C. Abiraterone and MVD3100 take androgen deprivation to a new level. J Natl Cancer Inst 2011;103(3): 175-6
13. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-Term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61(5): 1285-90
14. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-Term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010;11(11):1066-73
15. Shelley MD, Kumar S, Wilt T, et al. A systematic review and meta-Analysis of randomised trials of neo-Adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev 2009; 35(1):9-17
16. Elfiky AA, Jiang Z. The PI3 kinase signaling pathway in prostate cancer. Curr Cancer Drug Targets 2013;13(2): 157-64
17. Yoshimoto M, Cunha IW, Coudry RA, et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007;97(5):678-85
18. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8
19. Barbieri CE, Baca SC, Lawrence MS, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012;44(6): 685-9
20. Huang S, Gulzar ZG, Salari K, et al. Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness. Oncogene 2012;31(37):4164-70
21. MacInnis RJ, Antoniou AC, Eeles RA, et al. Prostate cancer segregation analyses using 4390 families from UK and Australian population-based studies. Genet Epidemiol 2010;4(1):42-50
22. Eeles RA, Olama AA, Benlloch S, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 2013;45(4): 385-91
23. Hazelett DJ, Rhie SK, Gaddis M, et al. Comprehensive functional annotation of 77 prostate cancer risk loci. PLoS Genet 2014;10(1):e1004102
24. Leongamornlert D, Saunders E, Dadaev T, et al. Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. Br J Cancer 2014;110(6): 1663-72
25. Moskaluk CA, Duray PH, Cowan KH, et al. Immunohistochemical expression of pi-class glutathione S-Transferase is down-regulated in adenocarcinoma of the prostate. Cancer 1997;79(8):1595-9
26. Filella X, Foj L, Milà M, et al. PCA3 in the detection and management of early prostate cancer. Tumour Biol 2013;34(3): 1337-47
27. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009; 27(18):2924-30
28. Thompson IM Jr, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. JAMA 2006; 296(19):2329-35
29. Resnick MJ, Koyama T, Fan KH, et al. Long-Term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013;368(5):436-45
30. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358(12):1250-61
31. Chade DC, Eastham J, Graefen M, et al. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: A systematic review of the literature. Eur Urol 2012;61(5):961-71
32. Parekh A, Graham PL, Nguyen PL. Cancer control and complications of salvage local therapy after failure of radiotherapy for prostate cancer: A systematic review. Semin Radiat Oncol 2013;23(3):222-34
33. Bibault JE, Fumagalli I, Ferté C, et al. Personalized radiation therapy and biomarker-driven treatment strategies: A systematic review. Cancer Metastasis Rev 2013;32(3-4):479-92
34. Tran PT, Hales RK, Zeng J, et al. Tissue biomarkers for prostate cancer radiation therapy. Curr Mol Med 2012;12(6):772-87
35. Choudhury AD, Eeles R, Freedland SJ, et al. The role of genetic markers in the management of prostate cancer. Eur Urol 2012;62(4):577-87
36. Kachroo N, Gnanapragasam VJ. The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: A systematic review. J Cancer Res Clin Oncol 2013;139(1):1-24
37. Agrawal S, Dunsmuir WD. Molecular markers in prostate cancer. Part I: Predicting lethality. Asian J Androl 2009;11(1):14-21
38. Sutcliffe P, Hummel S, Simpson E, et al. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: A systematic review. Health Technol Assess 2009;13(5):iii-xi-xiii.1-219
39. Roach M 3rd, Waldman F, Pollack A. Predictive models in external beam radiotherapy for clinically localized prostate cancer. Cancer 2009;115(13 Suppl):3112-20
40. Pollack A, Grignon DJ, Heydon KH, et al. Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-Term total androgen blockade: An analysis of RTOG 8610. J Clin Oncol 2003;21(7): 1238-48
41. Che M, DeSilvio M, Pollack A, et al. Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: A study based on RTOG 9202. Int J Radiat Oncol Biol Phys 2007; 69(4):1117-23
42. Chakravarti A, Heydon K, Wu CL, et al. Radiation Therapy Oncology Group. Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: An analysis from the Radiation Therapy Oncology Group protocol 86-10. J Clin Oncol 2003;21(17):3328-34
43. Pollack A, DeSilvio M, Khor LY, et al. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol 2004;22(11):2133-40
44. Chakravarti A, DeSilvio M, Zhang M, et al. Prognostic value of p16 in locally advanced prostate cancer: A study based on Radiation Therapy Oncology Group Protocol 9202. J Clin Oncol 2007;25(21):3082-9
45. Castro E, Eeles R. The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl 2012;14(3):409-14
46. Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013;31(14):1748-57
47. Zafarana G, Ishkanian AS, Malloff CA, et al. Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy. Cancer 2012;118(16):4053-62
48. Locke JA, Zafarana G, Ishkanian AS, et al. NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy. Clin Cancer Res 2012;18(1):308-16
49. Kumareswaran R, Ludkovski O, Meng A, et al. Chronic hypoxia compromises repair of DNA double-strand breaks to drive genetic instability. J Cell Sci 2012; 125(Pt 1):189-99
50. Bindra RS, Schaffer PJ, Meng A, et al. Alterations in DNA repair gene expression under hypoxia: Elucidating the mechanisms of hypoxia-induced genetic instability. Ann N Y Acad Sci 2005;1059:184-95
51. Milosevic M, Warde P, Ménard C, et al. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin Cancer Res 2012;18(7):2108-14
52. Vergis R, Corbishley CM, Norman AR, et al. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: A retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 2008;9(4):342-51
53. Vergis R, Corbishley CM, Thomas K, et al. Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation. Int J Radiat Oncol Biol Phys 2010;78(1):35-41
54. Pollack A, Cowen D, Troncoso P, et al. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: ki-67, bcl-2, bax, and bcl-x. Cancer 2003;97(7):1630-8
55. Miyake H, Fujisawa M. Prognostic prediction following radical prostatectomy for prostate cancer using conventional as well as molecular biological approaches. Int J Urol 2013;20(3):301-11
56. Lopergolo A, Zaffaroni N. Biomolecular markers of outcome prediction in prostate cancer. Cancer 2009;115(13 Suppl):3058-67
57. Febbo PG. Genomic approaches to outcome prediction in prostate cancer. Cancer 2009;115(13):3046-57
58. Erho N, Crisan A, Vergara IA, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One 2013;8(6):e66855
59. Cheville JC, Karnes RJ, Therneau TM, et al. Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J Clin Oncol 2008;26(24):3930-6
60. Pallua JD, Schaefer G, Seifarth C, et al. MALDI-MS tissue imaging identification of biliverdin reductase B overexpression in prostate cancer. J Proteomics 2013;91: 500-14
61. Arrabal-Polo MA, Jiménez-Pacheco A, Mijan-Ortiz JL, et al. Relationship between biopsy Gleason score and radical prostatectomy specimen Gleason score in patients undergoing sextant vs 12 core biopsies. Arch Esp Urol 2010;63(9):791-6
62. Sebo TJ, Cheville JC, Riehle DL, et al. Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer. Am J Surg Pathol 2002;26(4):431-9
63. Rubio J, Ramos D, Lopez-Guerrero JA, et al. Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. Eur Urol 2005;48(5):745-51
64. Tollefson MK, Karnes RJ, Kwon ED, et al. Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: The Mayo model. Mayo Clin Proc 2014;89(3):308-18
65. Brewster SF, Oxley JD, Trivella M, et al. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol 1999;161(4): 1238-43
66. Oxley JD, Winkler MH, Parry K, et al. p53 and bcl-2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy. BJU Int 2002;89(1):27-32
67. Wu TT, Hsu YS, Wang JS, et al. The role of p53, bcl-2 and E-cadherin expression in predicting biochemical relapse for organ confined prostate cancer in Taiwan. J Urol 2003;170(1):78-81
68. Hirata H, Hinoda Y, Kikuno N, et al. Bcl2-938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy. J Urol 2009;181(4):1907-12
69. Donovan MJ, Osman I, Khan FM, et al. Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease. BJU Int 2010;105(4):462-7
70. Bedolla R, Prihoda TJ, Kreisberg JI, et al. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and AKT activation. Clin Cancer Res 2007;13(13): 3860-7
71. Chaux A, Peskoe SB, Gonzalez-Roibon N, et al. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Mod Pathol 2012;25(11): 1543-9
72. Rhodes DR, Sanda MG, Otte AP, et al. Multiplex biomarker approach for determining risk of prostate-specific antigendefined recurrence of prostate cancer. J Natl Cancer Inst 2003;95(9):661-8
73. Loric S, Paradis V, Gala JL, et al. Abnormal E-cadherin expression and prostate cell blood dissemination as markers of biological recurrence in cancer. Eur J Cancer 2001; 37(12):1475-81
74. Aaltomaa S, Lipponen P, Viitanen J, et al. Prognostic value of CD44 standard, variant isoforms 3 and 6 and-catenin expression in local prostate cancer treated by radical prostatectomy. Eur Urol 2000;38(5):555-62
75. Gupta A, Lotan Y, Ashfaq R, et al. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol 2009;55(5):1124-33
76. Henshall SM, Quinn DI, Lee CS, et al. Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. Clin Cancer Res 2001;7(3):544-50
77. Halvorsen OJ, Hostmark J, Haukaas S, et al. Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma. Cancer 2000;88(2):416-24
78. Castro E, David O, Goh CL, et al. Effect of germ-line BRCA mutations in biochemical relapse and survival after treatment for localized prostate cancer. J Clin Oncol 2013;31(suppl 6):abstr 29
79. Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: A retrospective study. Lancet Oncol 2011;12(3):245-55
80. Cuzick J. Prognostic value of a cell cycle progression score for men with prostate cancer. Recent Results Cancer Res 2014;202:133-40
81. Freedland SJ, Gerber L, Reid J, et al. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol Biol Phys 2013;86(5):848-53
82. Cooperberg MR, Simko JP, Cowan JE, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol 2013;31(11):1428-34
83. Cooperberg M, Simko J, Falzarano S, et al. Development and validation of the biopsy-based genomic prostate score (GPS) as a predictor of high grade or extracapsular prostate cancer to improve patient selection for active surveillance. AUA Annual Meeting; 4-8 May 2013. San Diego, CA; Abstract 2131
84. Irshad S, Bansal M, Castillo-Martin M, et al. A molecular signature predictive of indolent prostate cancer. Sci Transl Med 2013;5(202):202ra122
85. Kim WT, Kim WJ. MicroRNAs in prostate cancer. Prostate Int 2013;1(1):3-9
86. O'Kelly F, Marignol L, Meunier A, et al. MicroRNAs as putative mediators of treatment response in prostate cancer. Nat Rev Urol 22 2012;9(7):397-407
87. Schaefer A, Jung M, Mollenkopf HJ, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 2010;126(5):1166-76
88. Casanova-Salas I, Rubio-Briones J, Calatrava A, et al. Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy. J Urol 2014. [Epub ahead of print]
89. Li B, Shi XB, Nori D, et al. Down-regulation of microRNA 106b is involved in p21-mediated cell cycle arrest in response to radiation in prostate cancer cells. Prostate 2011;71(6):567-74
90. Leung CM, Li SC, Chen TW, et al. Comprehensive microRNA profiling of prostate cancer cells after ionizing radiation treatment. Oncol Rep 2014;31(3):1067-78
91. Stott-Miller M, Zhao S, Wright JL, et al. Validation study of genes with hypermethylated promoter regions associated with prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev 2014. [Epub ahead of print]
92. Maldonado L, Brait M, Loyo M, et al. GSTP1 promoter methylation is associated with recurrence in early stage prostate cancer. J Urol 2014;pii: S0022-5347(14): 03413-12
93. Zhang P, Singh A, Yegnasubramanian S, et al. Loss of Kelch-like ECH-Associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther 2010;9(2):336-46
94. Marks L, Young S, Natarajan S. MRI-ultrasound fusion for guidance of targeted prostate biopsy. Curr Opin Urol 2013;23(1):43-50
95. Ukimura O, De Castro Abreu AL, Gill IS, et al. Image visibility of cancer to enhance targeting precision and spatial mapping biopsy for focal therapy of prostate cancer. BJU Int 2013;111(8):E354-64
96. Gnanapragasam VJ. Unlocking the molecular archive: The emerging use of formalin-fixed paraffin-embedded tissue for biomarker research in urological cancer. BJU Int 2010;105(2):274-8
97. Rogerson L, Darby S, Jabbar T, et al. Application of transcript profiling in formalin-fixed paraffin-embedded diagnostic prostate cancer needle biopsies. BJU Int 2008;102(3):364-70
98. Kluth M, Harasimowicz S, Burkhardt L, et al. Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer. Int J Cancer 2014. [Epub ahead of print]
99. Grupp K, Höhne TS, Prien K, et al. Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy. Exp Mol Pathol 2013;95(2):227-34
100. Weischenfeldt J, Simon R, Feuerbach L, et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 2013;23(2):159-70
101. Jeetle SS, Fisher G, Yang ZH, et al. Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer. Virchows Arch 2012;461(2):103-7
102. Berney DM, Gopalan A, Kudahetti S, et al. Ki-67 and outcome in clinically localised prostate cancer: Analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer 2009;100(6):888-93